Pirofsky B, Campbell S M, Montanaro A
J Clin Immunol. 1982 Apr;2(2 Suppl):7S-14S. doi: 10.1007/BF00918361.
Subjects with primary immunodeficiency received modified immune serum globulin (IGIV) intravenously at various dose levels in long-term therapeutic studies. Therapy was effective and essentially free from adverse reactions. Two pertinent observations were made relating to the attained levels of serum IGG. Over a dose range of 100-225 mg/kg, the serum IgG level directly reflects the dosage administered. Sequential analysis of serum levels of IgG demonstrated three patient populations in 14 subjects receiving 150 mg/kg. The largest group, nine patients, had progressive reduction of serum IgG values compatible with the half-life of the reagent, with a return to the original serum IgG level in four weeks. A second population of four patients had a slower reduction of serum IgG over the four-week period. IgG values were significantly elevated over baseline values at the time of the next due infusion. In one subject serum IgG values varied greatly with rapid drops and elevations unrelated to the infusion.
在长期治疗研究中，原发性免疫缺陷患者接受了不同剂量水平的静脉注射改良免疫血清球蛋白（IGIV）治疗。治疗效果良好，且基本无不良反应。关于血清免疫球蛋白G（IgG）达到的水平有两项相关观察结果。在100 - 225毫克/千克的剂量范围内，血清IgG水平直接反映给药剂量。对接受150毫克/千克治疗的14名受试者的血清IgG水平进行序贯分析，发现有三类患者群体。最大的一组有9名患者，其血清IgG值逐渐降低，符合该试剂的半衰期，四周后恢复到原来的血清IgG水平。第二组有4名患者，在四周内血清IgG下降较慢。在下一次预定输注时，IgG值比基线值显著升高。在一名受试者中，血清IgG值变化很大，出现与输注无关的快速下降和升高。
